Bridget E. Bunner

Array ( [id] => 17168880 [patent_doc_number] => 20210322550 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => ANTIBODY-CONTAINING FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/346421 [patent_app_country] => US [patent_app_date] => 2021-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23005 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17346421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18597251 [patent_doc_number] => 20230272045 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => IL-1 RECEPTOR ANTAGONIST (IL-1 RA) FUSION PROTEINS BINDING TO THE EXTRACELLULAR MATRIX [patent_app_type] => utility [patent_app_number] => 18/001480 [patent_app_country] => US [patent_app_date] => 2021-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31100 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18707459 [patent_doc_number] => 20230330033 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => DESIGNED ANTIBODY-BOUND NANOPARTICLES [patent_app_type] => utility [patent_app_number] => 17/907372 [patent_app_country] => US [patent_app_date] => 2021-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19992 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17907372 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18497397 [patent_doc_number] => 20230220027 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => GROWTH FACTOR COMPOSITION FOR CELL CULTURE-PRODUCED MEAT [patent_app_type] => utility [patent_app_number] => 18/000724 [patent_app_country] => US [patent_app_date] => 2021-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000724 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17314505 [patent_doc_number] => 20210403553 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => COMBINATION THERAPY FOR TREATMENT OF DISEASE [patent_app_type] => utility [patent_app_number] => 17/330716 [patent_app_country] => US [patent_app_date] => 2021-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51806 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17330716 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18964212 [patent_doc_number] => 11897963 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-13 [patent_title] => Anti-Jagged1 antigen binding proteins [patent_app_type] => utility [patent_app_number] => 17/320128 [patent_app_country] => US [patent_app_date] => 2021-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 87 [patent_no_of_words] => 39937 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17320128 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18420206 [patent_doc_number] => 20230174667 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => INHIBITION OF SARS-COV-2 INFECTION THROUGH SYNDECANS [patent_app_type] => utility [patent_app_number] => 17/924427 [patent_app_country] => US [patent_app_date] => 2021-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3893 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17924427 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17399652 [patent_doc_number] => 20220041742 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => Methods for Treating Multiple Myeloma [patent_app_type] => utility [patent_app_number] => 17/317789 [patent_app_country] => US [patent_app_date] => 2021-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27402 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17317789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17314538 [patent_doc_number] => 20210403586 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => MUTANT OF RANKL AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING OSTEOPOROSIS [patent_app_type] => utility [patent_app_number] => 17/317252 [patent_app_country] => US [patent_app_date] => 2021-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9399 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 200 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17317252 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18536081 [patent_doc_number] => 20230241168 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS WITH AND WITHOUT A T CELL INHIBITORY PROTEIN AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/923208 [patent_app_country] => US [patent_app_date] => 2021-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 110218 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -148 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17923208 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18496164 [patent_doc_number] => 20230218716 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING ATRIAL FIBRILLATION [patent_app_type] => utility [patent_app_number] => 17/997666 [patent_app_country] => US [patent_app_date] => 2021-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14880 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17997666 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19931755 [patent_doc_number] => 12304952 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-20 [patent_title] => Antibody constructs for DLL3 and CD3 [patent_app_type] => utility [patent_app_number] => 17/236467 [patent_app_country] => US [patent_app_date] => 2021-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 14 [patent_no_of_words] => 46746 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17236467 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20663680 [patent_doc_number] => 12605430 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-04-21 [patent_title] => High-activity blood coagulation factor XI mutant Ala570Thr [patent_app_type] => utility [patent_app_number] => 18/025398 [patent_app_country] => US [patent_app_date] => 2021-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 16 [patent_no_of_words] => 0 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18025398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18449590 [patent_doc_number] => 20230190866 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => PEPTIDE FOR THE TREATMENT OF CYTOKINE STORM SYNDROME [patent_app_type] => utility [patent_app_number] => 17/918299 [patent_app_country] => US [patent_app_date] => 2021-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6171 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17918299 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18436076 [patent_doc_number] => 20230183370 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => STEM CELL IMMUNOMODULATORY THERAPY FOR COVID-19 INFECTION [patent_app_type] => utility [patent_app_number] => 17/916502 [patent_app_country] => US [patent_app_date] => 2021-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12114 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17916502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16964206 [patent_doc_number] => 20210215705 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-15 [patent_title] => ANTIHUMAN BAFF ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/214585 [patent_app_country] => US [patent_app_date] => 2021-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5723 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17214585 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18420179 [patent_doc_number] => 20230174640 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => Use of Anti-IL-6 Antibody, e.g., Clazakizumab for Treatment/Prevention of ARDS Associated with Coronavirus (COVID-19) Infection [patent_app_type] => utility [patent_app_number] => 17/911808 [patent_app_country] => US [patent_app_date] => 2021-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34537 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17911808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18246035 [patent_doc_number] => 11602598 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2023-03-14 [patent_title] => Prefilled syringe with pegfilgrastim having optimized dose and methods related thereto [patent_app_type] => utility [patent_app_number] => 17/198404 [patent_app_country] => US [patent_app_date] => 2021-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 14 [patent_no_of_words] => 6581 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17198404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17369965 [patent_doc_number] => 20220025017 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => BTLA FUSION PROTEIN AGONISTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/188912 [patent_app_country] => US [patent_app_date] => 2021-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17188912 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18110863 [patent_doc_number] => 20230003743 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING AN ALLERGY OR ANAPHYLAXIS [patent_app_type] => utility [patent_app_number] => 17/801238 [patent_app_country] => US [patent_app_date] => 2021-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28608 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17801238 [rel_patent_id] =>[rel_patent_doc_number] =>)